Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


GlaxoSmithKline investigating bribery of foreign doctors

GSK allegedly offered doctors flexible travel arrangements and free samples that were later flipped for money

Just ask Hewlett-Packard, Alcoa and Avon — the U.S. government is taking foreign bribery seriously in 2014. Now, pharmaceutical giant GlaxoSmithKline (GSK) could be the next to feel the bribery sting.

The company announced on April 16 that it is investigating claims into possible bribery of foreign doctors in Jordan and Lebanon. The Wall Street Journal reports that GSK offered these doctors flexible travel arrangements and free samples that were later flipped for money.

According to one source, GSK gave Jordanian doctors up to 60 free samples of the vaccine Synflorix, which were later sold at up to $70 a vial. In Lebanon, meanwhile, GSK allegedly provided Synflorix to doctors for free as well as made payments to “key opinion-leader” doctors in order to flush out competition.

Emails reviewed by the WSJ also detail abuse of company travel regulations. Jordanian doctors would be given free business-class tickets by the company to attend conferences, but they would then flip the tickets for economy-class seats, allowing spouses or others to come along for free due to the change in value.

GSK says that it does not believe it has a systemic problem with bribery and that these charges are isolated. It also noted in a statement that it has a zero tolerance policy for bribery and holds strict compliance controls in place for the region.

“In total, we employ around 200 people in Jordan, Lebanon and Iraq in our pharmaceuticals operations and these allegations relate to a small number of individuals in these countries,” the company’s statement to the WSJ said.

However, there are still many steps to go in GSK’s investigation. As Marcus Christian of Mayer Brown recently wrote for InsideCounsel, Foreign Corrupt Practices Act violations are inherently tricky because of the many foreign regulations involved in the Act’s enforcement. “To minimize risk in the process, companies should have an investigations protocol in place ahead of time and, once an investigation is underway, they should be careful to evaluate the collateral consequences of every step of the investigation under foreign law before acting,” Christian said.


For more on bribery in legal news, check out these recent articles:

Former Direct Access Partners heads charged in bribery scheme

U.K. releases guidelines for new Bribery Act

HP to pay $108 million over foreign bribery charges

Japanese trading company pays second FCPA penalty in three years

Assistant Editor

author image

Zach Warren

Zach Warren is Assistant Editor of InsideCounsel magazine, where he oversees online content submissions and administers InsideCounsel's enewsletters. Zach specializes in new media and multimedia...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.